Todd K. Rosengart

From Wikitia
Jump to navigation Jump to search
Todd K. Rosengart
Add a Photo
Born (1960-01-24) January 24, 1960 (age 64)
Brooklyn, New York
NationalityAmerican
Alma mater
  • Northwestern University
  • New York University
Occupation
  • Cardiothoracic Surgeon
  • Educator
  • Researcher

Todd K. Rosengart (born January 24, 1960) is an American cardiothoracic surgeon, educator, and researcher, currently serving as the Chair of the Michael E. DeBakey Department of Surgery and Vice President for Hospital Operations and Quality Improvements at Baylor College of Medicine (BCM). [1] [2] In addition, he serves as the DeBakey-Bard Chair and professor of heart and vascular disease at the Texas Heart Institute. [3] He has been a leading researcher in cardiac angiogenesis and regeneration and is known for performing the world's first viral-based gene cardiac transfer procedure. [4] [5][6][7] and for his contributions to medical education and technology entrepreneurship[8][9]. Dr. Rosengart is recognized for his expertise in procedures such as bypass surgery, valve repair, and heart transplantation [10]

Early life and education

Born in Brooklyn, New York and brother to American lawyer, Mathew S. Rosengart.[11]. He completed his M.D. with honors from Northwestern University in 1983 under the mentorship of Dr. Michael Lesch, known for co-discovering the Lesch-Nyhan syndrome [12]. After graduation, he completed an internship and residency in general surgery at New York University Medical Center in 1985, a research fellowship at the National Heart, Lung, and Blood Institute (NIH) in 1987, and a thoracic surgery residency at New York Hospital in 1991.[1] Furthering his training, Rosengart moved to London, UK, to become a senior registrar at The Hospital for Sick Children. He completed his training at The Harley Street Clinic, working with Jaroslav Stark, a pioneer in the use of mathematics to study biological systems. [13]

Career

Prior to joining BCM, Rosengart held several significant positions at the State University of New York at Stony Brook (SUNY-Stony Brook), including professor and chair of the Department of Surgery and Chief of Cardiothoracic Surgery. He also served as the co-director of the Stony Brook Heart Center.[14]

Throughout his career, Rosengart has made substantial contributions to cardiothoracic surgery and heart and vascular disease education, noted for performing the world's first viral-based cardiac gene transfer procedure. [15] Rosengart has made progress in gene therapy to encourage the heart to grow new blood vessels, potentially offering a long-term cure for heart disease; already, 1,000 patients have received the experimental therapy with encouraging results, although objective evidence is still needed to verify its effectiveness. [16] He is co-founder of Vitals.com, now one of the largest medical consumerism companies in the U.S. and XyloCor Therapeutics,[17][18] a gene therapy company. Moreover, he has secured approximately $15 million in research grants and holds thirteen U.S. patents.[19][20]

Research and publications

Rosengart is a respected researcher and NIH-funded scientist and has over 200 published papers credited to him, with more than 13,500 citations and an h-index of 61.[21][22] He served as the Editor-In-Chief of the Seminar in Thoracic and Cardiovascular Surgery from 2012 to 2020.[23]

Memberships

He holds memberships in several professional societies, including the Leducq Foundation Scientific Advisory Committee, the American College of Cardiology, the American Association for Thoracic Surgery and the American Surgical Association. [24] He served as president of the Society of Surgical Chairs (2019) and co-editor of the Seminars in Thoracic and Cardiovascular Surgery (2013-2016).[25][26] He is the current Society of Surgical Chair liaison member to the American College of Surgeons Surgical Research Committee.[27]

References

  1. ↑ 1.0 1.1 "trosenga". Baylor College of Medicine. Retrieved 2023-07-27.
  2. ↑ "Baylor St. Luke's Medical Center Appoints Todd Rosengart, MD, to Hospital Board of Directors | St. Luke's Health | St. Luke's Health". stlukeshealth. Retrieved 2023-08-02.
  3. ↑ "Todd Rosengart, MD". The Texas Heart Institute. Retrieved 2023-07-27.
  4. ↑ Mathison, Megumi; Rosengart, Todd K. (2018-03-01). "Heart regeneration: The endothelial cell comes first". The Journal of Thoracic and Cardiovascular Surgery. 155 (3): 1128–1129. doi:10.1016/j.jtcvs.2017.09.106. ISSN 0022-5223. PMID 29452462.
  5. ↑ Rosengart, T. K.; Lee, L. Y.; Patel, S. R.; Sanborn, T. A.; Parikh, M.; Bergman, G. W.; Hachamovitch, R.; Szulc, M.; Kligfield, P. D.; Okin, P. M.; Hahn, R. T.; Devereux, R. B.; Post, M. R.; Hackett, N. R.; Foster, T. (1999-08-03). "Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease". Circulation. 100 (5): 468–474. doi:10.1161/01.cir.100.5.468. ISSN 1524-4539. PMID 10430759.
  6. ↑ Rosengart, Todd K.; Lee, Leonard Y.; Patel, Shailen R.; Kligfield, Paul D.; Okin, Peter M.; Hackett, Neil R.; Isom, O. Wayne; Crystal, Ronald G. (October 1999). "Six-Month Assessment of a Phase I Trial of Angiogenic Gene Therapy for the Treatment of Coronary Artery Disease Using Direct Intramyocardial Administration of an Adenovirus Vector Expressing the VEGF121 cDNA". Annals of Surgery. 230 (4): 466. ISSN 0003-4932.
  7. ↑ "Innovative approach brings cell-reprograming therapy for heart failure closer to reality". ScienceDaily. Retrieved 2023-08-02.
  8. ↑ "Company". xylocor.com. Retrieved 2023-08-02.
  9. ↑ AG, BIOCOM (2018-12-06). "XyloCor Therapeutics bags US$17m in Series A financing". european-biotechnology.com. Retrieved 2023-08-02.
  10. ↑ "Researchers explore novel strategy to improve the reprogramming efficiency of human fibroblasts". News-Medical.net. 2022-01-06. Retrieved 2023-08-02.
  11. ↑ "The Man of Steel – Boston College Law School Magazine". Retrieved 2023-08-02.
  12. ↑ Bell, Scott; Kolobova, Ilaria; Crapper, Liam; Ernst, Carl (2016-09-24). "Lesch-Nyhan Syndrome: Models, Theories, and Therapies". Molecular Syndromology. 7 (6): 302–311. doi:10.1159/000449296. ISSN 1661-8769.
  13. ↑ "Jaroslav Stark". Imperial College London. Retrieved 2023-08-02.
  14. ↑ "History of the Department | Renaissance School of Medicine at Stony Brook University". renaissance.stonybrookmedicine.edu. Retrieved 2023-08-02.
  15. ↑ "Todd Rosengart, MD". The Texas Heart Institute. Retrieved 2023-08-02.
  16. ↑ "TIME Magazine: How To Mend A Broken Heart --PAGE 1-- NOVEMBER 22, 1999". meiac.es. Retrieved 2023-08-02.
  17. ↑ George, Cindy (2019-02-05). "Cardiothoracic surgeon Todd Rosengart, M.D., discusses his career as a medical problem-solver". TMC News. Retrieved 2023-08-02.
  18. ↑ "Company". www.xylocor.com. Retrieved 2023-07-27.
  19. ↑ "Todd Rosengart, MD". The Texas Heart Institute. Retrieved 2023-08-02.
  20. ↑ "Google Patents". patents.google.com. Retrieved 2023-08-02.
  21. ↑ "RePORT ⟩ RePORTER". reporter.nih.gov. Retrieved 2023-08-02.
  22. ↑ "Rosengart T[author] - Search Results - PubMed". PubMed. Retrieved 2023-07-27.
  23. ↑ "New Surgical Chairs Playbook Guides Current and Aspiring Surgical Leaders". ACS. Retrieved 2023-08-02.
  24. ↑ "Leadership |". Retrieved 2023-08-02.
  25. ↑ "Membership Directory - Society of Surgical Chairs". web4.facs.org. Retrieved 2023-08-02.
  26. ↑ "Dr. Todd K. Rosengart Appointed Co-Editor of Seminars in Thoracic and Cardiovascular Surgery | Renaissance School of Medicine at Stony Brook University". renaissance.stonybrookmedicine.edu. Retrieved 2023-08-02.
  27. ↑ "ACS Surgical Research Committee". ACS. Retrieved 2023-08-02.

External links

Add External links

This article "Todd K. Rosengart" is from Wikipedia. The list of its authors can be seen in its historical. Articles taken from Draft Namespace on Wikipedia could be accessed on Wikipedia's Draft Namespace.

Retrieved from "https://wikitia.com/index.php?title=Todd_K._Rosengart&oldid=184050"